Valentina S. Mozgunova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentina S. Mozgunova has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Anna R. Volkova
Pavlov First Saint Petersburg State Medical University
7 shared publications - Galina V. Semikova
Pavlov First Saint Petersburg State Medical University
5 shared publications - B. G. Luckichev
Pavlov University
2 shared publications - Elena N. Ostrouchova
Pavlov University
2 shared publications - Анна Владимировна Лискер
Pavlov First Saint Petersburg State Medical University
2 shared publications - Василевский Дмитрий Игоревич
Pavlov First St. Petersburg State Medical University
2 shared publications
Latest Publications
- Open Access
- 22 October 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 184 (4) , 56-62
The first experience of application endoscopic sleeve gastroplasty in Russia: case series report
INTRODUCTION . Obesity is one of the most important problems of modern society, which requires the development of effective treatment methods. Endoscopic sleeve gastroplasty (ESG) is a minimally invasive approach to the treatment of obesity, which makes it possible to achieve significant weight loss and improve metabolic parameters. However, to date, there have been no studies on this technique in Russia. The OBJECTIVE was to evaluate the efficacy, safety, and aspects of the application of ESG using the example of two clinical cases. METHODS AND MATHERIALS. We present four cases of patients with stage II and III of obesity who underwent ESG. The patients met the inclusion criteria determined based on the Brazilian Consensus on Indications and Contraindications for this procedure. RESULTS . All patients demonstrated positive results after the procedure, including significant weight loss and improved quality of life without severe adverse events. CONCLUSION . This study is the first in Russia to highlight the importance of ESG as a promising method of obesity treatment. Further research is needed to assess the long-term outcomes and safety of this procedure.
- 22 October 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 184 (4) , 56-62
Open AccessThe first experience of application endoscopic sleeve gastroplasty in Russia: case series report
INTRODUCTION . Obesity is one of the most important problems of modern society, which requires the development of effective treatment methods. Endoscopic sleeve gastroplasty (ESG) is a minimally invasive approach to the treatment of obesity, which makes it possible to achieve significant weight loss and improve metabolic parameters. However, to date, there have been no studies on this technique in Russia. The OBJECTIVE was to evaluate the efficacy, safety, and aspects of the application of ESG using the example of two clinical cases. METHODS AND MATHERIALS. We present four cases of patients with stage II and III of obesity who underwent ESG. The patients met the inclusion criteria determined based on the Brazilian Consensus on Indications and Contraindications for this procedure. RESULTS . All patients demonstrated positive results after the procedure, including significant weight loss and improved quality of life without severe adverse events. CONCLUSION . This study is the first in Russia to highlight the importance of ESG as a promising method of obesity treatment. Further research is needed to assess the long-term outcomes and safety of this procedure.
- Open Access
- 10 May 2023
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 4 (2) , 69-74
Role of metabolic surgery in remission of type 2 diabetes mellitus in patients with obesity
Type 2 diabetes mellitus and obesity are two socially significant diseases, the prevalence of which has now assumed pandemic proportions. Obesity, as a rule, precedes the development of type 2 diabetes, being the most powerful risk factor for the development of this disease. In patients with obesity and type 2 diabetes with a BMI >35 kg/m2, bariatric surgery is recommended if glycemic control cannot be achieved after several attempts at non-surgical treatment of obesity. There is no doubt the effectiveness of bariatric surgery not only in the treatment of obesity, but also in achieving remission of type 2 diabetes. It seems relevant to study the predictors of achieving remission of type 2 diabetes, as well as factors that can worsen the prognosis. The purpose of the review: to study the effectiveness of metabolic surgery in achieving remission of type 2 DM, as well as predictors of remission of type 2 DM in obese patients after bariatric surgery.
- 10 May 2023
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 4 (2) , 69-74
Open AccessRole of metabolic surgery in remission of type 2 diabetes mellitus in patients with obesity
Type 2 diabetes mellitus and obesity are two socially significant diseases, the prevalence of which has now assumed pandemic proportions. Obesity, as a rule, precedes the development of type 2 diabetes, being the most powerful risk factor for the development of this disease. In patients with obesity and type 2 diabetes with a BMI >35 kg/m2, bariatric surgery is recommended if glycemic control cannot be achieved after several attempts at non-surgical treatment of obesity. There is no doubt the effectiveness of bariatric surgery not only in the treatment of obesity, but also in achieving remission of type 2 diabetes. It seems relevant to study the predictors of achieving remission of type 2 diabetes, as well as factors that can worsen the prognosis. The purpose of the review: to study the effectiveness of metabolic surgery in achieving remission of type 2 DM, as well as predictors of remission of type 2 DM in obese patients after bariatric surgery.
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 12 (4)
The role of glucagon-like peptide 1 in the remission of type 2 diabetes mellitus in obese patients after metabolic surgery
Роль глюкагоноподобного пептида 1 в ремиссии сахарного диабета 2 типа у пациентов с ожирением после метаболической хирургии
- 1 January 2023
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 12 (4)
Open AccessThe role of glucagon-like peptide 1 in the remission of type 2 diabetes mellitus in obese patients after metabolic surgery
Роль глюкагоноподобного пептида 1 в ремиссии сахарного диабета 2 типа у пациентов с ожирением после метаболической хирургии
- 1 January 2023
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 12 (1)
Remission of type 2 diabetes mellitus in obese patients after bariatric surgery
Ремиссия сахарного диабета 2 типа у пациентов с ожирением после бариатрических операций
- 1 January 2023
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 12 (1)
Remission of type 2 diabetes mellitus in obese patients after bariatric surgery
Ремиссия сахарного диабета 2 типа у пациентов с ожирением после бариатрических операций
- Open Access
- 12 May 2021
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 23 (1) , 89-94
Glucagon-like peptid-1 in obese and diabetic patients after bariatric interventions
The relationship between the level of glucagon-like peptide-1 and repeated weight gain was evaluated in 31 patients suffering from grade IIIII obesity and type 2 diabetes mellitus after bariatric interventions for 3 years. It was found that the level of stimulated glucagon-like peptide-1 significantly increased by the third day after sleeve gastroplasty and gastroschunt compared to the initial parameters (p = 0.001 for obese patients; p = 0.000 for obese patients and diabetes mellitus). In the plateau phase (body weight retention) after bariatric intervention, the level of stimulated glucagon-like peptide-1 in obese patients and patients suffering from obesity in combination with diabetes mellitus did not significantly differ from the indicators of healthy individuals. There was no association between the level of glucagon-like peptide-1 and repeated weight gain. This may be due to the limited contribution of glucagon-like peptide-1 to body weight dynamics after bariatric interventions and the predominance of patient compliance. Thus, the level of stimulated glucagon-like peptide-1 at baseline, on the third day and in the plateau phase after bariatric intervention was not associated with the value of repeated weight gain.
- 12 May 2021
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 23 (1) , 89-94
Open AccessGlucagon-like peptid-1 in obese and diabetic patients after bariatric interventions
The relationship between the level of glucagon-like peptide-1 and repeated weight gain was evaluated in 31 patients suffering from grade IIIII obesity and type 2 diabetes mellitus after bariatric interventions for 3 years. It was found that the level of stimulated glucagon-like peptide-1 significantly increased by the third day after sleeve gastroplasty and gastroschunt compared to the initial parameters (p = 0.001 for obese patients; p = 0.000 for obese patients and diabetes mellitus). In the plateau phase (body weight retention) after bariatric intervention, the level of stimulated glucagon-like peptide-1 in obese patients and patients suffering from obesity in combination with diabetes mellitus did not significantly differ from the indicators of healthy individuals. There was no association between the level of glucagon-like peptide-1 and repeated weight gain. This may be due to the limited contribution of glucagon-like peptide-1 to body weight dynamics after bariatric interventions and the predominance of patient compliance. Thus, the level of stimulated glucagon-like peptide-1 at baseline, on the third day and in the plateau phase after bariatric intervention was not associated with the value of repeated weight gain.
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (3)
Insulin therapy in patients with type 2 diabetes mellitus: a focus on therapeutic education
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (3)
Insulin therapy in patients with type 2 diabetes mellitus: a focus on therapeutic education
- 26 June 2020
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 24 (4) , 46-54
Glycemic variability in patients with diabetes mellitus and different stages of diabetic nephropathy
The relevance of the study of glycemic variability in patients with diabetes mellitus and diabetic nephropathy is due to disability of the able-bodied population and high mortality against the background of the almost irreversible progression of diabetic nephropathy. The article highlights modern ideas about the influence of various factors on the occurrence of diabetic nephropathy and its course. The article is devoted to a review of current recommendations on diabetes mellitus and diabetic nephropathy; the etiopathogenesis of diabetic nephropathy was described in detail. The role of the kidneys in glucose homeostasis, renal gluconeogenesis, and glucose reabsorption by the kidneys in healthy and in pathology is described. Detailed expositions of glycemic variability parameters, their changes in patients with diabetes mellitus depending on the stage of diabetic kidney damage are presented. The role of the kidneys in maintaining energy homeostasis, impaired glucose homeostasis in conditions of chronic kidney disease is described. We analyzed different options for insulin therapy, their advantages, and disadvantages in patients with diabetes mellitus with diabetic nephropathy. The presented material is extremely relevant for the development and implementation in the clinical practice of glycemic control methods to optimize treatment tactics, prevent the formation of microvascular complications, and early disability of patients with diabetes mellitus.
- 26 June 2020
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 24 (4) , 46-54
Glycemic variability in patients with diabetes mellitus and different stages of diabetic nephropathy
The relevance of the study of glycemic variability in patients with diabetes mellitus and diabetic nephropathy is due to disability of the able-bodied population and high mortality against the background of the almost irreversible progression of diabetic nephropathy. The article highlights modern ideas about the influence of various factors on the occurrence of diabetic nephropathy and its course. The article is devoted to a review of current recommendations on diabetes mellitus and diabetic nephropathy; the etiopathogenesis of diabetic nephropathy was described in detail. The role of the kidneys in glucose homeostasis, renal gluconeogenesis, and glucose reabsorption by the kidneys in healthy and in pathology is described. Detailed expositions of glycemic variability parameters, their changes in patients with diabetes mellitus depending on the stage of diabetic kidney damage are presented. The role of the kidneys in maintaining energy homeostasis, impaired glucose homeostasis in conditions of chronic kidney disease is described. We analyzed different options for insulin therapy, their advantages, and disadvantages in patients with diabetes mellitus with diabetic nephropathy. The presented material is extremely relevant for the development and implementation in the clinical practice of glycemic control methods to optimize treatment tactics, prevent the formation of microvascular complications, and early disability of patients with diabetes mellitus.